PMID- 21933595
OWN - NLM
STAT- MEDLINE
DCOM- 20120427
LR  - 20151119
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 124
IP  - 16
DP  - 2011 Aug
TI  - Infliximab protects against pulmonary emphysema in smoking rats.
PG  - 2502-6
AB  - BACKGROUND: It is widely accepted that tumor necrosis factor-alpha (TNF-alpha) plays an 
      important role in the pathogenesis of emphysema. This study aimed at 
      investigating the protective effects of anti-TNF-alpha antibody, infliximab, in the 
      development of emphysema induced by passive smoking in rats. METHODS: Thirty-nine 
      rats were randomly divided into a normal control group (group 1), an emphysema 
      group (group 2), and an infliximab-intervention group (group 3). Rat models of 
      emphysema were established by exposure to cigarette smoking daily for 74 days. 
      After 1 month, the infliximab intervention group was treated with infliximab via 
      subcutaneous injection. The levels of TNF-alpha, IL-8 and vascular endothelial growth 
      factor (VEGF) in bronchoalveolar lavage fluid (BALF) were measured with enzyme 
      linked immunosorbent assay (ELISA). The number and classification of cells in the 
      BALF were measured. Lung tissue sections stained by hematoxylin and eosin (HE) 
      were observed, and mean linear intercept (MLI) and mean alveolar numbers (MAN) 
      were measured. Terminal deoxynucleotidyl transferase-mediated dUTP nick end 
      labeling (TUNEL) methods were used to examine the percentage of positive cells 
      and distribution of apoptotic cells. RESULTS: The levels of TNF-alpha and IL-8 in 
      BALF were higher in group 2 than in group 1 and group 3. The MLI was greater in 
      group 2 than that in group 1 and group 3 while MAN was decreased. The 
      concentration of VEGF in BALF of group 2 was significantly decreased as compared 
      with group 1. The total cells and neutrophils number was significantly increased 
      in group 2 as compared with group 1 and group 3, so was the percentage of 
      neutrophils. The number of TUNEL positive cells in the alveolar septa was 
      significantly increased in group 2 as compared with group 1 and group 3. 
      CONCLUSION: Infliximab protects against cigarette smoking-induced emphysema by 
      reducing airway inflammation, attenuating alveolar septa cell apoptosis and 
      improving pathological changes.
FAU - Zhang, Xiang-Yan
AU  - Zhang XY
AD  - Department of Respiratory Medicine, Guizhou Provincial People's Hospital, 
      Guiyang, Guizhou 550002, China.
FAU - Zhang, Cheng
AU  - Zhang C
FAU - Sun, Qian-Yun
AU  - Sun QY
FAU - Li, Dan
AU  - Li D
FAU - Luo, Rong-Rong
AU  - Luo RR
FAU - Wan, Zi-Fen
AU  - Wan ZF
FAU - Ye, Xian-Wei
AU  - Ye XW
FAU - Liu, Wei-Jia
AU  - Liu WJ
FAU - Rao, Shan-Shan
AU  - Rao SS
FAU - Han, Jing
AU  - Han J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Interleukin-8)
RN  - 0 (Tobacco Smoke Pollution)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Bronchoalveolar Lavage Fluid/chemistry/cytology
MH  - Infliximab
MH  - Interleukin-8/metabolism
MH  - Male
MH  - Pulmonary Alveoli/cytology/drug effects
MH  - Pulmonary Emphysema/chemically induced/metabolism/*prevention & control
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tobacco Smoke Pollution/*adverse effects
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2011/09/22 06:00
MHDA- 2012/04/28 06:00
CRDT- 2011/09/22 06:00
PHST- 2011/09/22 06:00 [entrez]
PHST- 2011/09/22 06:00 [pubmed]
PHST- 2012/04/28 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2011 Aug;124(16):2502-6.